Furthermore, the same research group showed a differential MAGI2 abundance in biopsies of patients with different glomerulopathies using immunofluorescence, revealing a marked downregulation of this protein in FSGS [8]. This evidence concerns the gene MAGI2 and lipoprotein glomerulopathy.